Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > A layman's thoughts on Roche and Adaptive Phase 3.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 04, 2024 11:17pm

158 Views

Post# 35862383

RE:RE:A layman's thoughts on Roche and Adaptive Phase 3.

The Phase 2 trials Reo-17 and GOBLET-1 were both adaptive clinical trials and a Phase 3 confirmation study is simply a follow-on adaptive designed study based on the previous Phase 2, as I have posted here beforehand.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?